ISSN : 3023-7505
  • Home
  • About The Journal
  • Editorial Board
  • Instructions for Authors
  • Contact
Current Issue
Ahead Of Print
Archive
Search
Most Popular
Download Articles Read Articles
Automated Perimetry
Carbonic Anhydrase Inhibitors
Intra Ocular Lens Power Calculation and Optic Biometry...
Visual Field Defects in Glaucoma
Visual Field Defect and Retinal Nerve Fiber Layer Defect in a Case of Optic Nerve Head Drusen...
Current Minimal Invasive Angle Procedures Without Implants for the Treatment of Glaucoma...
Intra Ocular Lens Power Calculation and Optic Biometry...
Automated Perimetry
Carbonic Anhydrase Inhibitors
Visual Field Defect and Retinal Nerve Fiber Layer Defect in a Case of Optic Nerve Head Drusen...
PureSee Kesintisiz Yüksek Kalitede Görüş
TJ-CEO 2019 , Vol 14 , Num 2
Turkish Abstract Abstract Free Full Text Similar Articles Mail to Author
Sustained Elevation of Intraocular Pressure After Multiple Intravitreal Antivascular Endothelial Growth Factor Injection Agents: Comparison of Bevacizumab and Ranibizumab
Mehmet Özgür ÇUBUK1, Zeynep AKTAŞ2, Yücel ÜÇGÜL3, Armağan YUVARLAK4, Murat HASANREİSOĞLU2, Şengül ÖZDEK5, Gökhan GÜRELİK5
1Uz. Dr., İstanbul Eğitim ve Araştırma Hastanesi, Göz, İstanbul, Türkiye
2Doç. Dr., Gazi Üniversitesi Tıp Fakültesi, Göz, Ankara, Türkiye
3Uz. Dr., Abant İzzet Baysal Üniversitesi Eğitim ve Araştırma Hastanesi, Göz, Bolu, Türkiye
4Uz. Dr., Şanlıurfa Eğitim ve Araştırma Hastanesi, Göz, Şanlıurfa, Türkiye
5Prof. Dr., Gazi Üniversitesi Tıp Fakültesi, Göz, Ankara, Türkiye
Purpose: To evaluate the long-term intraocular pressure (IOP) changes after intravitreal bevacizumab and ranibizumab and to compare their impacts on IOP.

Method: The medical charts of patients treated with intravitreal anti-vascular endothelial growth factor anti-vascular endothelial growth factor (VEGF) (bevacizumab-ranibizumab) for retinal vascular disorders or age-related macular degeneration (AMD) from January 2011 to January 2015 were retrospectively reviewed. Patients with any other history of steroid therapy and intraocular surgery except cataract surgery were excluded. Baseline IOP was defi ned as the pre-injection mean IOP for two consecutive visits before the first injection and the final IOP was defi ned as the mean IOP for two consecutive visits measured at first month after the last injection. Signifi cant IOP elevation was defi ned as IOP elevation higher than 5 mmHg or final IOP higher than 21 mmHg provided that it is higher than baseline IOP.

Results: Hundred eighty three eyes (143 with AMD and 40 with diabetic macular oedema) from 160 patients were included in this study. IOP elevation after intravitreal anti-VEGF therapy was statistically signifi cant (P=0,0001 paired samples t-test). Sixteen eyes (8.7%) had IOP elevations greater than 5 mmHg, Ten (5.4%) had final IOPs higher than 21 mmHg. After the exclusion of patients with primary open angle glaucoma (PAOG) and pseudoexfoliation syndrome (PXS), two of 132 eyes in the ranibizumab group and two of 22 eyes in the bevacizumab group had final IOP values higher than 21 mmHg. The differences were statistically signifi cant (p=0.040, Pearson chi-square test).

Conclusion: IOP rise is more signifi cant in patients who received bevacizumab compared to ranibizumab. Hence ranibizumab injection might be recommended as a first choice especially in patients with POAG. Keywords : Vascular endothelial growth factor, ranibizumab, bevacizumab, intraocular pressure

PureSee Kesintisiz Yüksek Kalitede Görüş
Home
About The Journal
Editorial Board
Instructions for Authors
Contact